查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1717086

细胞免疫疗法市场：2025-2030 年全球预测（按类型、技术类型、适应症和设施类别）

Cellular Immunotherapy Market by Type, Technology Type, Indication, Institution Category - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2024年细胞免疫治疗市场价值将达到118.9亿美元，2025年将成长至132.9亿美元，复合年增长率为12.03%，到2030年将达到235.2亿美元。

主要市场统计数据
基准年2024年 118.9亿美元
预计2025年 132.9亿美元
预测年份 2030 235.2亿美元
复合年增长率（%） 12.03%

细胞免疫疗法已成为现代医学的一个有希望的前沿领域，它提供了利用人体自身免疫系统潜力的创新治疗方案。本报告对快速发展的细胞免疫治疗领域进行了深入分析，提供了有关转型趋势、策略性细分、区域市场和主要行业参与者的关键见解。近年来，基因工程、免疫调节和细胞治疗技术的快速发展，彻底改变了恶性肿瘤等复杂疾病的治疗方法。这些进步不仅扩展了我们对免疫细胞功能的理解，也为个人化治疗铺平了道路，确保有针对性的行动，同时最大限度地减少脱靶效应。

随着时间的推移，该行业已从传统方法发展到利用先进生物技术的更灵活的框架。研究和临床专家现在能够在精确设计的治疗方法中利用细胞成分的力量，从而获得更有效的结果并提高患者的生存率。对治疗创新和精准化的追求持续刺激着对研发的大量投资以及学术机构和私人公司之间的伙伴关係。本执行摘要汇集了广泛的市场研究见解，全面介绍了细胞免疫疗法的当前趋势和未来方向。

改变细胞免疫疗法市场

细胞免疫治疗领域正在经历变革时期重新定义治疗模式和市场动态的变化。在过去的十年中，先进的基因重组技术与免疫肿瘤学的融合重塑了治疗策略。嵌合体抗原受体 (CAR) T 细胞疗法和基于树突状细胞的方法的出现标誌着高度个人化介入的更广泛转变。这些创新促使人们摆脱「一刀切」的治疗方法，转而根据每个患者的基因特征和疾病特征制定个人化治疗方案。

技术进步正在加速治疗方法从概念走向临床的步伐。体外细胞处理方法的不断改进和免疫调节剂的突破使得治疗方法具有更高的功效和安全性。生物技术创新与既定临床实践的快速融合正在缩短开发时间、提高针对肿瘤特异性抗原的精确度以及优化给药方案。此外，数据分析和人工智慧的进步有助于改善患者分层和反应监测，这对于成功的临床结果至关重要。

此外，不断发展的法律规范和活性化的资金筹措力度创造了有利于高风险、高回报创新的环境。投资者和市场相关人员对细胞免疫疗法的长期益处越来越有信心，临床试验的扩大和商业性兴趣的日益增长就是明证。随着生物技术公司、学术研究中心和全球製药公司之间战略伙伴关係的形成，细胞免疫疗法正在从一种利基市场转变为一种主流治疗途径，并将彻底改变多种疾病的患者护理。

细胞免疫疗法关键环节分析

对市场的更深入分析揭示了支持细胞免疫疗法策略方向的多方面细分。按类型细分评估了该领域的多种方法，包括CAR T细胞疗法、树突细胞疗法、NK细胞疗法和肿瘤浸润淋巴细胞疗法。这些治疗方法旨在针对免疫系统的特定方面，以克服各种恶性肿瘤带来的独特挑战。同时，从技术类型来看市场细分，可以透过部署细胞激素和免疫调节剂以及单株抗体来检查市场。每种技术都提供了一种互补的机制来活化或控制免疫系统，从而达到治疗效果。

由于细胞免疫疗法满足了多样化的临床需求，基于适应症的市场区隔提供了更清晰的策略前景。该领域的产品针对的是 B 细胞恶性肿瘤、肝癌、前列腺癌和肾细胞癌等棘手的癌症。这种细分凸显了设计新治疗方法所需的精确度，并证明了根据特定肿瘤适应症量身定制治疗的临床重要性。此外，基于设施类别的显着细分提供了进一步的见解。分析涵盖学术研究机构、生物技术和製药公司、承包组织、医院和研究组织。每个机构在药物发现、开发和商业化过程中都发挥着独特的作用，塑造了创新治疗方法从实验室到病患床边的整个历程。

了解这种细分可以帮助市场参与企业调整他们的研究和商业策略。不同治疗方法、技术类型、临床适应症和组织角色的复杂组合创造了复杂的市场机会。利用从各个维度获得的见解，产业领导者可以优化产品系列、加强合作并确定未满足的临床需求，从而推动细胞免疫疗法的未来创新。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 癌症和自体免疫疾病的发生率不断上升，推动了对创新治疗方法的需求。
      • 患者意识和倡导的增强正在推动对先进治疗方案的需求
      • 临床试验和研究合作投资的增加推动了快速创新
    • 限制因素
      • 高昂的生产和营运成本阻碍了新兴治疗方法的可及性和扩充性
    • 机会
      • 整合人工智慧主导的调查方法和先进的诊断技术
      • 密切合作与伙伴关係推动先进细胞免疫疗法发展
    • 任务
      • 降低智慧财产权纠纷风险并应对专利保护的复杂性
  • 市场区隔分析
    • 类型：实施CAT T细胞细胞免疫疗法，推动造血系统恶性肿瘤的治疗
    • 机构类别：扩大学术机构中细胞免疫疗法的临床研究范围
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

第六章 细胞免疫治疗市场（按类型）

  • CAR-T细胞疗法
  • 树突细胞疗法
  • NK细胞疗法
  • 肿瘤浸润淋巴细胞治疗

第七章细胞免疫治疗市场（依技术类型）

  • 细胞激素和免疫调节剂
  • 单株抗体

第 8 章 细胞免疫治疗市场（依适应症划分）

  • B细胞恶性肿瘤
  • 肝癌
  • 摄护腺癌
  • 肾臟细胞癌

第九章细胞免疫治疗市场（依机构分类）

  • 学术机构
  • 生物技术和製药公司
  • 承包组织
  • 医院
  • 研究机构

第 10 章：美洲细胞免疫疗法市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第11章亚太细胞免疫治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

12. 欧洲、中东和非洲细胞免疫疗法市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Adaptimmune Therapeutics PLC
  • Adicet Bio, Inc.
  • Apac Biotech Private Limited
  • AstraZeneca PLC
  • Atara Biotherapeutics, Inc.
  • Bellicum Phamaceuticals, Inc.
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb Company
  • Celyad Oncology SA
  • Corning Incorporated
  • Dendreon Pharmaceuticals LLC
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Glycostem Therapeutics BV
  • Immatics NV
  • Inovio Pharmaceuticals, Inc.
  • Iovance Biotherapeutics, Inc.
  • Johnson & Johnson Services, Inc.
  • JW Therapeutics（Shanghai）Co., Ltd.
  • Lonza Group Ltd.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
Product Code: MRR-7C50F2739738

The Cellular Immunotherapy Market was valued at USD 11.89 billion in 2024 and is projected to grow to USD 13.29 billion in 2025, with a CAGR of 12.03%, reaching USD 23.52 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 11.89 billion
Estimated Year [2025] USD 13.29 billion
Forecast Year [2030] USD 23.52 billion
CAGR (%) 12.03%

Cellular immunotherapy has emerged as a promising frontier in modern medicine, offering innovative treatment solutions that harness the potential of the body's own immune system. This report provides an in-depth analysis of the fast-evolving cellular immunotherapy landscape, highlighting transformative trends, strategic segmentation, and key insights into regional markets and major industry players. In recent years, breakthroughs in genetic engineering, immunomodulation, and cellular therapy techniques have revolutionized the way malignancies and other complex diseases are treated. Such advancements have not only expanded the understanding of immune cell functionalities but have also paved the way for individualized therapies that ensure targeted action with minimized off-target effects.

Over time, the industry has progressed from traditional methods to a more agile framework that leverages advanced biotechnologies. Researchers and clinical experts are now able to harness the power of cellular components in precisely engineered therapies, leading to more effective outcomes and improved patient survivability. The drive for innovation and precision in treatments continues to spur significant investments in research and development as well as partnerships between academic and private entities. This executive summary consolidates findings from extensive market research, offering a holistic view of current trends and future directions in cellular immunotherapy.

Transformative Shifts in the Cellular Immunotherapy Landscape

The cellular immunotherapy sector is undergoing transformative shifts that are redefining treatment paradigms and market dynamics. Over the past decade, the integration of sophisticated genetic modification techniques with immuno-oncology has reshaped therapeutic strategies. The emergence of chimeric antigen receptor (CAR) T-cell therapies and dendritic cell-based approaches is indicative of a broader movement towards highly personalized interventions. These innovations have facilitated a move away from a one-size-fits-all approach, ensuring that treatments are tailored to the individual patient's genetic profile and disease characteristics.

Technological advancements have accelerated the pace at which therapies move from concept to clinic. Continuous improvements in ex vivo cell processing methods, along with breakthroughs in immunomodulatory agents, have resulted in therapies with greater efficacy and safety profiles. The rapid convergence of biotechnological innovation with established clinical practices has led to reduced development timelines, increased precision in targeting tumor-specific antigens, and the optimization of dosing regimens. In addition, enhanced data analytics and artificial intelligence have facilitated better patient stratification and response monitoring, which are essential for successful clinical outcomes.

Furthermore, evolving regulatory frameworks and increased funding initiatives have fostered an environment that is conducive to high-risk, high-reward innovations. Investors and market stakeholders are increasingly confident in the long-term benefits of cellular immunotherapies, as evidenced by expanding clinical trials and growing commercial interest. The strategic partnerships formed between biotech firms, academic research centers, and global pharmaceutical companies are transforming cellular immunotherapy from a niche niche venture to a mainstream treatment modality that promises to revolutionize patient care across a wide spectrum of conditions.

Key Segmentation Insights in Cellular Immunotherapy

Deep analysis of the market reveals a multi-dimensional segmentation that underpins the strategic directions of cellular immunotherapy. The segmentation based on type evaluates the diverse approaches within the field, including CAR T-Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, and Tumor-Infiltrating Lymphocytes Therapy. These treatment modalities are designed to target specific aspects of the immune system and overcome the unique challenges posed by different malignancies. In parallel, when the segmentation is viewed through the technology type, the market is studied across the deployment of Cytokines & Immunomodulators and Monoclonal Antibodies. Each technology provides complementary mechanisms by which the immune system can be activated or regulated to achieve therapeutic benefits.

The market's segmentation based on indication further tones the strategic landscape, as cellular immunotherapies are tailored to diverse clinical needs. Products in this segment are targeting challenging ailments such as B-Cell Malignancies, Liver Cancer, Prostate Cancer, and Renal Cell Carcinoma. This segmentation highlights the precision with which new therapies are designed and signifies the clinical importance of tailoring treatments to specific oncologic indications. Moreover, a critical segmentation based on institution category offers additional insights. Here, the analysis spans across academic institutes, biotech and pharmaceutical companies, contract organizations, hospitals, and research institutes. Each institution plays a unique role in the discovery, development, and commercialization process, shaping the overall journey of innovative therapies from the lab bench to the patient bedside.

Understanding these segmentation layers aids market participants in tailoring their research and commercial strategies. The intricate interplay of different types of therapies, technology types, clinical indications, and institutional roles generates a mosaic of market opportunities. By leveraging insights from each of these dimensions, industry leaders can optimize product portfolios, enhance collaborative efforts, and identify unmet clinical needs that drive future innovation in cellular immunotherapy.

Based on Type, market is studied across CAR T-Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, and Tumor-Infiltrating Lymphocytes Therapy.

Based on Technology Type, market is studied across Cytokines & Immunomodulators and Monoclonal Antibodies.

Based on Indication, market is studied across B-Cell Malignancies, Liver Cancer, Prostate Cancer, and Renal Cell Carcinoma.

Based on Institution Category, market is studied across Academic Institutes, Biotech & Pharmaceutical Companies, Contract Organizations, Hospitals, and Research Institutes.

Key Regional Insights in Global Cellular Immunotherapy Markets

A regional analysis of the cellular immunotherapy market reveals significant variations in adoption, investment, and regulatory support across different geographies. North America, particularly within the Americas, continues to set the pace by offering a robust clinical and research infrastructure that accelerates innovation and commercialization. The mature market dynamics, driven by substantial research funding and a supportive regulatory environment, provide optimal conditions for cutting-edge therapies to be developed and implemented. Moving over to the Europe, Middle East & Africa region, the landscape is characterized by a confluence of advanced research hubs and emerging markets that are rapidly expanding their capacity to innovate. These regions benefit from diverse funding sources, strategic collaborations across borders, and early-stage clinical trials which propel the region to the forefront of technological adoption. Meanwhile, the Asia-Pacific region is marked by an accelerating pace of technological adoption and growing investment in biotechnology. With an increase in government initiatives and rising healthcare awareness, the region is establishing itself as a pivotal market for both development and regional clinical studies.

Each of these geographies offers unique opportunities and challenges. The Americas provide an environment where clinical efficacy and market readiness converge, while Europe, Middle East & Africa present a blend of mature and emerging markets, offering strategic entry and expansion platforms. The Asia-Pacific region stands out for its rapid growth, with favorable demographics and cost-effective clinical trial environments driving a surge in innovation and application of cellular immunotherapies. The regional nuances in market demand, regulatory conditions, and infrastructure investments play a pivotal role in shaping the future global landscape of cellular immunotherapy.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Driving Innovation in Cellular Immunotherapy

The landscape of cellular immunotherapy is shaped by the substantial contributions of several key companies who continue to drive the innovation and commercialization of advanced therapies. Leading the charge are companies such as Adaptimmune Therapeutics PLC and Adicet Bio, Inc., whose pioneering work has redefined treatment protocols through cutting-edge therapeutic designs. Apac Biotech Private Limited and AstraZeneca PLC have also established themselves as critical players by leveraging extensive research networks and large-scale manufacturing capabilities. Firms like Atara Biotherapeutics, Inc. and Bellicum Phamaceuticals, Inc. have embraced innovative approaches to cellular reprogramming, further enriching the therapeutic landscape.

Other major contributors include Bio-Rad Laboratories, Inc. and Bristol-Myers Squibb Company, which have integrated advanced diagnostic platforms to support the clinical application of these therapies. Organizations such as Celyad Oncology SA and Corning Incorporated have made significant strides in adapting cellular therapies to a range of oncologic indications, thereby expanding their utility. Contributions from Dendreon Pharmaceuticals LLC, Eli Lilly and Company, and F. Hoffmann-La Roche AG underscore the importance of robust clinical trials and regulatory approvals in accelerating the adoption of novel treatments. Companies like Gilead Sciences, Inc. and GlaxoSmithKline PLC have demonstrated unwavering commitment to research and development, while Glycostem Therapeutics B.V. and Immatics N.V. continue to push the boundaries with innovative molecular techniques.

Furthermore, major industry players including Inovio Pharmaceuticals, Inc., Iovance Biotherapeutics, Inc., and Johnson & Johnson Services, Inc. are setting new industry standards with their integrated research and commercialization strategies. JW Therapeutics (Shanghai) Co., Ltd., Lonza Group Ltd., Merck KGaA, Novartis AG, and Pfizer Inc. add considerable global clout, solidifying the market's trajectory toward wider clinical use. Through strategic collaborations, extensive research investments, and a relentless focus on patient outcomes, these companies are defining the future direction of cellular immunotherapy on a global scale.

The report delves into recent significant developments in the Cellular Immunotherapy Market, highlighting leading vendors and their innovative profiles. These include Adaptimmune Therapeutics PLC, Adicet Bio, Inc., Apac Biotech Private Limited, AstraZeneca PLC, Atara Biotherapeutics, Inc., Bellicum Phamaceuticals, Inc., Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, Celyad Oncology SA, Corning Incorporated, Dendreon Pharmaceuticals LLC, Eli Lilly and Company, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Glycostem Therapeutics B.V., Immatics N.V., Inovio Pharmaceuticals, Inc., Iovance Biotherapeutics, Inc., Johnson & Johnson Services, Inc., JW Therapeutics (Shanghai) Co., Ltd., Lonza Group Ltd., Merck KGaA, Novartis AG, and Pfizer Inc.. Actionable Recommendations for Industry Leaders

To capitalize on the evolving opportunities within cellular immunotherapy, industry leaders should consider several strategic approaches. First, it is imperative to invest in cutting-edge research and development initiatives that push the boundaries of current cellular therapy technologies. Embracing digital transformation, from data analytics to AI-driven precision medicine platforms, can yield significant improvements in clinical trials and patient outcomes. Leaders should actively pursue collaboration with academic institutions and biotechnology innovators to foster an environment of shared expertise and resource pooling.

Second, companies are encouraged to streamline regulatory and compliance processes by adopting proactive engagement strategies with regulatory authorities. This approach not only accelerates product development cycles but also helps in navigating complex global compliance landscapes effectively. Furthermore, exploring partnerships with contract organizations and research institutes can enhance operational efficiency, ensuring rigorous standards are met at each phase of clinical development.

Third, focusing on tailored market segmentation is crucial. By honing in on specific therapeutic modalities and indications, companies can better address unmet clinical needs and optimize product pipelines. This targeted approach will facilitate more efficient resource allocation and drive innovation in both research and commercialization. It is also important to gather real-world evidence to support the clinical claims of new therapies and to continually monitor patient responses. This iterative process can lead to fine-tuning therapies in line with ongoing clinical feedback.

Finally, industry leaders must be agile in adapting to regional market nuances. Differentiated strategies that address the unique regulatory, cultural, and economic landscapes of regions such as the Americas, Europe, Middle East & Africa, and Asia-Pacific are essential. Recognizing and leveraging local strengths while mitigating challenges posed by regulatory environments or market maturity will provide a competitive edge and foster sustainable growth in the global market.

Conclusion: Shaping the Future of Cellular Immunotherapy

In summary, the cellular immunotherapy market stands at a pivotal juncture, representing both immense promise and significant transformation. With the convergence of innovative therapeutic techniques, strategic market segmentation, and the relentless drive of pioneering companies, the industry is poised for rapid evolution. The integration of advanced data analytics, regulatory agility, and cross-sector collaborations underlines a commitment to patient-centric approaches that push the envelope of modern medicine.

The trends outlined in this report suggest a future where therapies are increasingly personalized, efficacious, and widely accessible. As stakeholders continue to refine and advance these groundbreaking treatments, the overall quality of life for patients battling complex malignancies is expected to improve markedly. This dynamic landscape not only offers unprecedented opportunities for clinical breakthroughs but also sets the stage for robust commercial growth and enhanced global healthcare standards.

The journey towards fully realizing the potential of cellular immunotherapy is marked by challenges that are continually being addressed through innovation and strategic foresight. The insights presented here serve as a foundation for further discussion and action among decision-makers who are committed to reshaping the future of cancer treatment and beyond.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cancer and autoimmune disorders driving demand for innovative cellular immunotherapy treatments
      • 5.1.1.2. Growing patient awareness and advocacy driving demand for advanced therapeutic options
      • 5.1.1.3. Rising investment in clinical trials and research collaborations driving rapid innovation
    • 5.1.2. Restraints
      • 5.1.2.1. High production and operational costs that hinder accessibility and scalability for emerging therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Integration of artificial intelligence-driven research methodologies and advanced diagnostics
      • 5.1.3.2. Stringent collaboration and partnership fueling advanced cellular immunotherapy
    • 5.1.4. Challenges
      • 5.1.4.1. Mitigating risks of intellectual property disputes and navigating complex patent protection
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Implementation of cellular immunotherapy in CAT T-cell to foster treatment of hematological malignancies
    • 5.2.2. Institution Category: Expanding applicability of cellular immunotherapy in academic institutes for clinical investigations
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cellular Immunotherapy Market, by Type

  • 6.1. Introduction
  • 6.2. CAR T-Cell Therapy
  • 6.3. Dendritic Cell Therapy
  • 6.4. NK Cell Therapy
  • 6.5. Tumor-Infiltrating Lymphocytes Therapy

7. Cellular Immunotherapy Market, by Technology Type

  • 7.1. Introduction
  • 7.2. Cytokines & Immunomodulators
  • 7.3. Monoclonal Antibodies

8. Cellular Immunotherapy Market, by Indication

  • 8.1. Introduction
  • 8.2. B-Cell Malignancies
  • 8.3. Liver Cancer
  • 8.4. Prostate Cancer
  • 8.5. Renal Cell Carcinoma

9. Cellular Immunotherapy Market, by Institution Category

  • 9.1. Introduction
  • 9.2. Academic Institutes
  • 9.3. Biotech & Pharmaceutical Companies
  • 9.4. Contract Organizations
  • 9.5. Hospitals
  • 9.6. Research Institutes

10. Americas Cellular Immunotherapy Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cellular Immunotherapy Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cellular Immunotherapy Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. AbbVie and Xilio therapeutics join forces to advance tumor-activated immunotherapies
    • 13.3.2. WashU Medicine's USD 10.8 million SPORE grant drives translational research for novel cell-based immunotherapies
    • 13.3.3. Vironexis Biotherapeutics pioneers innovation in cancer treatment with AAV-delivered T-cell immunotherapy
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Adaptimmune Therapeutics PLC
  • 2. Adicet Bio, Inc.
  • 3. Apac Biotech Private Limited
  • 4. AstraZeneca PLC
  • 5. Atara Biotherapeutics, Inc.
  • 6. Bellicum Phamaceuticals, Inc.
  • 7. Bio-Rad Laboratories, Inc.
  • 8. Bristol-Myers Squibb Company
  • 9. Celyad Oncology SA
  • 10. Corning Incorporated
  • 11. Dendreon Pharmaceuticals LLC
  • 12. Eli Lilly and Company
  • 13. F. Hoffmann-La Roche AG
  • 14. Gilead Sciences, Inc.
  • 15. GlaxoSmithKline PLC
  • 16. Glycostem Therapeutics B.V.
  • 17. Immatics N.V.
  • 18. Inovio Pharmaceuticals, Inc.
  • 19. Iovance Biotherapeutics, Inc.
  • 20. Johnson & Johnson Services, Inc.
  • 21. JW Therapeutics (Shanghai) Co., Ltd.
  • 22. Lonza Group Ltd.
  • 23. Merck KGaA
  • 24. Novartis AG
  • 25. Pfizer Inc.

LIST OF FIGURES

  • FIGURE 1. CELLULAR IMMUNOTHERAPY MARKET MULTI-CURRENCY
  • FIGURE 2. CELLULAR IMMUNOTHERAPY MARKET MULTI-LANGUAGE
  • FIGURE 3. CELLULAR IMMUNOTHERAPY MARKET RESEARCH PROCESS
  • FIGURE 4. CELLULAR IMMUNOTHERAPY MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 17. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 19. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. CELLULAR IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 25. CELLULAR IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CELLULAR IMMUNOTHERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CELLULAR IMMUNOTHERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TUMOR-INFILTRATING LYMPHOCYTES THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CYTOKINES & IMMUNOMODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY B-CELL MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY BIOTECH & PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CONTRACT ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 194. CELLULAR IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 195. CELLULAR IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2024